<DOC>
	<DOCNO>NCT01397422</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , placebo-controlled , 4-arm parallel group study evaluate tolerability efficacy three dose level ADS-5102 oral capsule , extend release formulation amantadine , dose daily treatment levodopa-induced dyskinesia ( LID ) subject Parkinson 's disease ( PD ) . The novel pharmacokinetic profile ADS-5102 expect achieve ) high amantadine plasma concentration daytime hour dyskinesia well motor non-motor symptom PD problematic , ii ) low amantadine plasma concentration overnight , may reduce sleep disturbance vivid dream occasionally associate amantadine , iii ) reduce initial rate rise plasma concentration , expect improve overall tolerability amantadine .</brief_summary>
	<brief_title>Extended Release Amantadine Safety Efficacy Study Levodopa-Induced Dyskinesia ( EASED Study )</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Amantadine</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Signed current IRB/IECapproved inform consent form Parkinson 's disease , per UK Parkinson 's Disease Society ( UKPDS ) Brain Bank Clinical Diagnostic Criteria On stable regimen antiparkinson 's medication , include levodopa preparation administer less three time daily , willing continue dos regimens study participation Experiencing troublesome dyskinesia follow levodopa dose ( peak dose dyskinesia ) Able understand complete standardize PD home diary , follow train History neurosurgical intervention relate Parkinson 's disease ( e.g . deep brain stimulation ) History seizure stroke/TIA within 2 year screen History cancer within 5 year screen , except adequately treat nonmelanomatous skin cancer , localize bladder cancer , nonmetastatic prostate cancer situ cervical cancer Estimated GFR &lt; 50 mL/min/1.73m2 Presence cognitive impairment , evidence MiniMental Status Examination ( MMSE ) score less 24 screening If female , pregnant lactating , positive pregnancy test result predose If sexually active female , surgically sterile least 2 year postmenopausal , agree utilize effective method contraception screen least 4 week completion study treatment Treatment investigational drug device within 30 day prior screen Treatment investigational biologic within 6 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Levodopa-induced dyskinesia</keyword>
	<keyword>Parkinsonism</keyword>
</DOC>